Mereo is a UK-based specialty biopharma company established to address the R&D and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo’s business model brings clear benefits to these companies, to investors, and to patients.
Large pharmaceutical companies’ pipelines have a significant number of promising new product candidates, but increasing P&L pressures and competition for R&D resources combined with strategic changes of direction mean that some of these candidates are not advanced. Mereo was established to acquire the most promising of these and ensure they fulfil their potential in a way that is mutually beneficial to both partners.
We first work with the pharmaceutical companies to identify novel pipeline product candidates in speciality and rare diseases that have the potential to address areas of high unmet medical need but that are not being progressed. Through an acquisition or licensing structure we then provide the financial and clinical development and operational expertise needed to accelerate progression of these products to the marketplace, creating value for all the respective stakeholders.
Mereo was incorporated in March 2015 and joined the London Stock Exchange’s AIM market in June 2016. Since incorporation, Mereo has raised over £105 million from institutional investors, including the leading healthcare investors Woodford, Invesco and from Novartis. In addition, in August 2017, a £20 million debt facility was agreed with Silicon Valley Bank and Kreos Capital of which £10 million has been drawn down.
The company acquired an initial portfolio of three pipeline product candidates from Novartis in July 2015. Building on Mereo’s business model to construct a diversified portfolio the company in-licensed an additional product from AstraZeneca in October 2017. Each of these four programmes comes with both pre-clinical and initial Phase 2 data, either in the disease indication we are developing or in a related disease indication.
Our team is highly experienced in clinical development, identifying new product opportunities, capital raising and structuring transactions.VIew Our Team
Our goal is to leverage Mereo’s innovative business model and resources to develop novel medicines for patients and to become a leader in specialty biopharma.View Our Strategy
Our Business Model
We focus on acquiring and delivering Phase 2 drugs to patients, whilst optimising the value of our product portfolio through flexible deal structures.View our business model